CD85j, also called ILT2, is a member of the immunoglobulin (Ig)-like transcripts (ILT) family of genes located on human chromosome 19 (the numerical subclassification refers to the members in the order of the gene on the chromosome). It is a 110-kDa transmembrane glycoprotein. ILT2 receptor is a NK receptor involved in inhibition of NK and T cells cytolytic activity and cytokine production. ILT2 is also known as leucocyte Ig-like receptor (LIR)-1 and monocyte / macrophage Ig-like receptor (MIR)-7. The protein has 4 extracellular Ig-SF domains, and 4 cytoplasmic ITIM motifs in the cytoplasmic tail. Both myeloid and lymphoid cells express ILT2. Among lymphoid cells, NK cells, T cell subsets and all peripheral B cells express ILT2. It is also expressed on monocytes, macrophages, and dendritic cells. Ligands for CD85j are non-classical class I HLA-G molecules, certain alleles of HLA-A and -B loci and the human cytomegalovirus gene product, UL18, a viral homolog of HLA class I molecules. The inhibitory function of CD85j has been explored mainly in NK and T cells. In NK cells, ILT2 inhibits the cytolysis of HLA-Class I-positive target cells. In T cells, ILT2 inhibits both signaling and cellular events that control the activation of T cells.